Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
HOME > LATEST
LATEST
-
BUSINESS Enhertu Nabs Pan-Tumor Indication in US: Daiichi Sankyo
April 9, 2024
-
BUSINESS GSK Japan Shooting for 80% Goal for Paid Paternity Leave in 2024
April 8, 2024
-
ORGANIZATION New LLP Coverage Scheme Intended for Generic Promotion: Payer Exec
April 8, 2024
-
BUSINESS Otsuka, Verily Join Forces to Run Mental Health Registry
April 8, 2024
-
ORGANIZATION Generic Rate Hits Record for 6th Straight Quarter in October-December: JGA
April 8, 2024
-
BUSINESS Japan Ethical Drug Sales Zoom 12.1% in February: Crecon
April 8, 2024
-
BUSINESS Keytruda Tops Japan Sales List for 6th Month in March: Encise
April 8, 2024
-
BUSINESS Kyowa Kirin Hopes Amgen-Partnered Eczema Drug to Rival or Even Eclipse Crysvita in Sales: CEO
April 5, 2024
-
REGULATORY MOF Panel Begins Debate for FY2025 Budget Proposal, Mulls Spending Target
April 5, 2024
-
BUSINESS Rohto, Mitsui to Buy Singapore’s Chinese Medicine Firm for SGD800 Million
April 5, 2024
-
BUSINESS Nippon Shinyaku, MiNA Therapeutics Join Hands in Rare CNS Disorders
April 5, 2024
-
BUSINESS Healios Snaps Up Assets after Athersys’ Bankruptcy Filing
April 5, 2024
-
REGULATORY Japan Kicks Off New Reporting System for “Supply Risk” and “Supply Status”
April 4, 2024
-
BUSINESS Tarlige Winner in February GP Rep Promotion Rankings
April 4, 2024
-
BUSINESS Taisho’s Positive PIII Data Set Stage for Japan Filing of Insomnia Med
April 4, 2024
-
BUSINESS FDA OKs First Digital Therapeutic App for Depression: Otsuka
April 4, 2024
-
BUSINESS Chugai Offers 5% Pay Raise in 30-Year-Old Model Case
April 4, 2024
-
BUSINESS Mochida, Meiji Adds China for Epadel Sales Collaboration
April 4, 2024
-
BUSINESS Eisai to Divest Rights to 2 CNS Drugs to UK’s CNX in France, Algeria
April 4, 2024
-
BUSINESS Sawai Closes Sale of US Business to Taiwan CDMO
April 4, 2024
ページ
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…